FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890855006> ?p ?o ?g. }

• W2890855006 abstract "Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. A third of psoriatic patients develop PsA via unknown mechanisms. No reliable diagnostic markers are available for PsA, or prognostic biomarkers for PsA development in psoriasis. We previously uncovered a pro-inflammatory role for cathelicidin LL37 in lesional psoriasis skin. LL37 binds nucleic acids and stimulates plasmacytoid/myeloid dendritic cells (pDC, mDCs) to secrete type I interferon (IFN-I) and pro-inflammatory factors. LL37 becomes an autoantigen for psoriatic Th1-Th17/CD8 T cells. Anti-LL37 antibodies were detected in systemic lupus erythematosus, an autoimmune disease characterized by neutrophil-extracellular-traps release (NETosis) in target organs. LL37 can be substrate of irreversible post-translational modifications, citrullination or carbamylation, linked to neutrophil activity. Here we analyzed inflammatory factors, included LL37, in PsA and psoriasis plasma and PsA synovial fluids (SF)/biopsies. We show that LL37 (as a product of infiltrating neutrophils) and autoantibodies to LL37 are elevated in PsA, but not OA SF. Anti-LL37 antibodies correlate with clinical inflammatory markers. Anti-carbamylated/citrullinated-LL37 antibodies are present in PsA SF/plasma and, at lower extent, in psoriasis plasma, but not in controls. Plasma anti-carbamylated-LL37 antibodies correlate with PsA (DAS44) but not psoriasis (PASI) disease activity. Ectopic lymphoid structures, and deposition of immunoglobulin-(Ig)G-complexes (IC) co-localizing with infiltrating neutrophils, are observed in PsA and not OA synovial tissues (ST). Activated complement (C5a, C9), GM-CSF and IFN-I are up-regulated in PsA and not OA synovia and in PsA and psoriasis plasma but not in HD. C9 and GM-CSF levels in PsA SF correlate with clinical inflammatory markers and DAS44 (C9) and with anti-carbamylated/citrullinated-LL37 antibodies (GM-CSF and IFN-I). Thus, we uncover a role for LL37 as a novel PsA autoantibody target and correlation studies suggest participation of anti-LL37 antibodies to PsA pathogenesis. Notably, plasma antibodies to carbamylated-LL37, which correlate with DAS44, suggest their use as new disease activity markers. GM-CSF and complement C5a and C9 elevation may be responsible for autoantigens release by neutrophils and their modification, fueling inflammation and autoreactivity establishment. Finally, targeting GM-CSF, C5a, C9 can be beneficial in PsA." @default.
• W2890855006 created "2018-09-27" @default.
• W2890855006 creator A5001758963 @default.
• W2890855006 creator A5004401304 @default.
• W2890855006 creator A5004485732 @default.
• W2890855006 creator A5008500196 @default.
• W2890855006 creator A5014431719 @default.
• W2890855006 creator A5018565069 @default.
• W2890855006 creator A5021325586 @default.
• W2890855006 creator A5022739370 @default.
• W2890855006 creator A5027197885 @default.
• W2890855006 creator A5028697486 @default.
• W2890855006 creator A5036523393 @default.
• W2890855006 creator A5040440600 @default.
• W2890855006 creator A5045989939 @default.
• W2890855006 creator A5047362905 @default.
• W2890855006 creator A5051526168 @default.
• W2890855006 creator A5052041110 @default.
• W2890855006 creator A5053063613 @default.
• W2890855006 creator A5053176930 @default.
• W2890855006 creator A5055735434 @default.
• W2890855006 creator A5069999699 @default.
• W2890855006 creator A5075368922 @default.
• W2890855006 creator A5078833835 @default.
• W2890855006 creator A5083687141 @default.
• W2890855006 creator A5085647114 @default.
• W2890855006 creator A5085697674 @default.
• W2890855006 creator A5087114501 @default.
• W2890855006 date "2018-09-12" @default.
• W2890855006 modified "2023-10-14" @default.
• W2890855006 title "Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA" @default.
• W2890855006 cites W1208141991 @default.
• W2890855006 cites W1497810899 @default.
• W2890855006 cites W1576065822 @default.
• W2890855006 cites W1597726496 @default.
• W2890855006 cites W1769013904 @default.
• W2890855006 cites W1855295630 @default.
• W2890855006 cites W1966553244 @default.
• W2890855006 cites W1974248935 @default.
• W2890855006 cites W1993983648 @default.
• W2890855006 cites W1996584569 @default.
• W2890855006 cites W2009074857 @default.
• W2890855006 cites W2014981269 @default.
• W2890855006 cites W2022039920 @default.
• W2890855006 cites W2031167276 @default.
• W2890855006 cites W2046637170 @default.
• W2890855006 cites W2052844959 @default.
• W2890855006 cites W2056112680 @default.
• W2890855006 cites W2059353973 @default.
• W2890855006 cites W2072460496 @default.
• W2890855006 cites W2083180635 @default.
• W2890855006 cites W2084951281 @default.
• W2890855006 cites W2085332488 @default.
• W2890855006 cites W2085793178 @default.
• W2890855006 cites W2091599164 @default.
• W2890855006 cites W2095712743 @default.
• W2890855006 cites W2095947548 @default.
• W2890855006 cites W2096620879 @default.
• W2890855006 cites W2100446659 @default.
• W2890855006 cites W2110956453 @default.
• W2890855006 cites W2113776905 @default.
• W2890855006 cites W2121134187 @default.
• W2890855006 cites W2123585444 @default.
• W2890855006 cites W2127735217 @default.
• W2890855006 cites W2134595043 @default.
• W2890855006 cites W2141522272 @default.
• W2890855006 cites W2146604395 @default.
• W2890855006 cites W2147060846 @default.
• W2890855006 cites W2157130851 @default.
• W2890855006 cites W2173239068 @default.
• W2890855006 cites W2284779242 @default.
• W2890855006 cites W2404253692 @default.
• W2890855006 cites W2561759163 @default.
• W2890855006 cites W2580329215 @default.
• W2890855006 cites W2613983133 @default.
• W2890855006 cites W2730693644 @default.
• W2890855006 cites W2741334054 @default.
• W2890855006 cites W2742950097 @default.
• W2890855006 cites W2769698474 @default.
• W2890855006 cites W2793302471 @default.
• W2890855006 cites W2794664176 @default.
• W2890855006 cites W2797853366 @default.
• W2890855006 cites W410437911 @default.
• W2890855006 cites W4241915332 @default.
• W2890855006 doi "https://doi.org/10.3389/fimmu.2018.01936" @default.
• W2890855006 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6154218" @default.
• W2890855006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30279686" @default.
• W2890855006 hasPublicationYear "2018" @default.
• W2890855006 type Work @default.
• W2890855006 sameAs 2890855006 @default.
• W2890855006 citedByCount "65" @default.
• W2890855006 countsByYear W28908550062019 @default.
• W2890855006 countsByYear W28908550062020 @default.
• W2890855006 countsByYear W28908550062021 @default.
• W2890855006 countsByYear W28908550062022 @default.
• W2890855006 countsByYear W28908550062023 @default.
• W2890855006 crossrefType "journal-article" @default.
• W2890855006 hasAuthorship W2890855006A5001758963 @default.
• W2890855006 hasAuthorship W2890855006A5004401304 @default.
• W2890855006 hasAuthorship W2890855006A5004485732 @default.

• next